$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

$avxl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000173112223002197 Filed on November 27, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.609M	$2.592M	$12.04M
YoY Change	-21.35%	-33.59%	-7.88%
% of Gross Profit
Research & Development	$8.684M	$10.06M	$43.72M
YoY Change	-28.03%	-11.6%	15.3%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$11.29M	$12.65M	$55.76M
YoY Change	-26.59%	-17.22%	-209.36%
Operating Profit	-$11.29M		-$55.76M
YoY Change	-26.59%		9.36%
Interest Expense	$2.164M	$1.772M	$5.520M
YoY Change	32.47%	745.94%	12624.76%
% of Operating Profit
Other Income/Expense, Net	$2.756M	$669.9K	$8.258M
YoY Change	15.21%	-32.63%	145.31%
Pretax Income	-$8.537M	-$10.21M	-$47.50M
YoY Change	-34.29%	-27.49%	-0.25%
Income Tax	$85.00K	-$63.95K	$10.00K
% Of Pretax Income
Net Earnings	-$8.622M	-$10.15M	-$47.51M
YoY Change	-33.53%	-29.0%	-0.99%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11		-$0.60
Diluted Earnings Per Share	-$0.11	-$0.12	-$0.60
COMMON SHARES
Basic Shares Outstanding	82.09M shares	81.95M shares	79.79M shares
Diluted Shares Outstanding	82.08M shares		79.79M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$143.8M	$151.0M	$151.0M
YoY Change	0.1%	1.25%	1.24%
Cash & Equivalents	$143.8M	$151.0M	$151.0M
Short-Term Investments
Other Short-Term Assets	$756.0K	$653.0K	$700.0K
YoY Change	15.31%	84.38%	97.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$148.1M	$154.4M	$154.4M
YoY Change	-0.2%	1.1%	1.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$148.1M	$154.4M	$154.4M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$148.1M	$154.4M	$154.4M
YoY Change	-0.2%	1.1%	1.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.292M	$4.322M	$4.300M
YoY Change	-18.84%	13.0%	12.42%
Accrued Expenses	$7.286M	$7.295M	$7.300M
YoY Change	3.45%	22.71%	22.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.50M	$12.53M	$12.50M
YoY Change	-5.68%	22.72%	22.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.50M	$12.53M	$12.50M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.50M	$12.53M	$12.50M
YoY Change	-5.68%	22.72%	22.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$301.7M	-$293.1M
YoY Change	16.69%	19.35%
Common Stock	$437.3M	$434.9M
YoY Change	11.08%	12.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$135.6M	$141.9M	$141.9M
YoY Change
Total Liabilities & Shareholders Equity	$148.1M	$154.4M	$154.4M
YoY Change	-0.2%	1.1%	1.11%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$8.622M	-$10.15M	-$47.51M
YoY Change	-33.53%	-29.0%	-0.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$7.318M	-$5.845M	-$27.79M
YoY Change	26.3%	44.54%	14.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$27.88M
YoY Change			32.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$59.00K	2.061M	$29.65M
YoY Change	-77.15%	84367.21%	39.29%
NET CHANGE
Cash From Operating Activities	-$7.318M	-5.845M	-$27.79M
Cash From Investing Activities
Cash From Financing Activities	$59.00K	2.061M	$29.65M
Net Change In Cash	-$7.259M	-3.784M	$1.866M
YoY Change	31.12%	-6.37%	-163.26%
FREE CASH FLOW
Cash From Operating Activities	-$7.318M	-$5.845M	-$27.79M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001314052
CY2022	avxl	Other Financing Expense OtherFinancingExpense		usd
CY2021	avxl	Other Financing Expense OtherFinancingExpense		usd
CY2022	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges		usd
CY2021	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges		usd
CY2022	avxl	Deferred Grant Income DeferredGrantIncome		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2021	avxl	Commitment Shares CommitmentShares		usd
CY2023	avxl	Commitment Shares CommitmentShares		usd
CY2022Q3	avxl	Deferred Tax Assets Research And Development Capitalization DeferredTaxAssetsResearchAndDevelopmentCapitalization		usd
CY2021Q3	avxl	Deferred Tax Assets Research And Development Capitalization DeferredTaxAssetsResearchAndDevelopmentCapitalization		usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount		usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount		usd
CY2023	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m		usd
CY2022	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m		usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2023	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382		usd
CY2022	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382		usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2023	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37606
CY2023	dei	Entity Registrant Name EntityRegistrantName	ANAVEX LIFE SCIENCES CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0608404
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 5th Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	20th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Country EntityAddressCountry	US
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10111
CY2023	dei	City Area Code CityAreaCode	844
CY2023	dei	Local Phone Number LocalPhoneNumber	689-3939
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	AVXL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	667000000	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82086511	shares
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	Melville, New York
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151024000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149158000	usd
CY2023Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2709000	usd
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3193000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	653000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	354000	usd
CY2023Q3	us-gaap	Assets Assets	154386000	usd
CY2022Q3	us-gaap	Assets Assets	152705000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4322000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3825000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7295000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5945000	usd
CY2023Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	917000	usd
CY2022Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	444000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	12534000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10214000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82066511	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82066511	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77942815	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77942815	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	82000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	78000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	434839000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387977000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293069000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245564000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	141852000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	154386000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152705000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12039000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9018000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43717000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37916000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32984000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	55756000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	50986000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	42002000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-55756000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-50986000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-42002000	usd
CY2023	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	25000	usd
CY2021	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	54000	usd
CY2023	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	2718000	usd
CY2022	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	3323000	usd
CY2021	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	4547000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6519000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	947000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	26000	usd
CY2023	avxl	Other Financing Expense OtherFinancingExpense	964000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-40000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-904000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-266000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8258000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3366000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4361000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47498000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47620000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37641000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	358000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	268000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47505000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47978000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37909000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79787596	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79787596	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76909993	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76909993	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69802960	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69802960	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47505000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47978000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37909000	usd
CY2023	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges	845000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	16370000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18379000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8231000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-484000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-5944000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4287000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	299000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-88000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	497000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-914000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	751000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1350000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	330000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2298000	usd
CY2023	avxl	Deferred Grant Income DeferredGrantIncome	-473000	usd
CY2021	avxl	Deferred Grant Income DeferredGrantIncome	-444000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27785000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24238000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30384000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27875000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20985000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	153219000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	707000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5551000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1467000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1776000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1010000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4108000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29651000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21288000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	153243000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1866000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2950000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	122859000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149158000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152108000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29249000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151024000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149158000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152108000	usd
CY2023	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	136000	usd
CY2022	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	327000	usd
CY2021	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	140000	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	27237000	usd
CY2021	avxl	Shares Issued Under Sales Agreement SharesIssuedUnderSalesAgreement	79108000	usd
CY2021	avxl	Less Sales Agreement Share Issue Costs LessSalesAgreementShareIssueCosts	-2438000	usd
CY2021	avxl	Shares Issued Pursuant To Registered Direct Offering SharesIssuedPursuantToRegisteredDirectOffering	50000000	usd
CY2021	avxl	Less Registered Direct Offering Share Issue Costs LessRegisteredDirectOfferingShareIssueCosts	-3097000	usd
CY2021	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	4108000	usd
CY2021	avxl	Shares Issued Pusuant To Exercise Of Warrants SharesIssuedPusuantToExerciseOfWarrants	1466000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8231000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37909000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	150817000	usd
CY2022	avxl	Shares Issued Under Sales Agreement SharesIssuedUnderSalesAgreement	20985000	usd
CY2022	avxl	Less Sales Agreement Share Issue Costs LessSalesAgreementShareIssueCosts	-723000	usd
CY2022	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	1011000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18379000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47978000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491000	usd
CY2023	avxl	Shares Issued Under2023 Purchase Agreement Initial Commitment Shares SharesIssuedUnder2023PurchaseAgreementInitialCommitmentShares	845000	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	27875000	usd
CY2023	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	1776000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16370000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-47505000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	141852000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_z6qiTKflTLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zdIdNWMOYl8g">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Revenue Recognition Incentives RevenueRecognitionIncentives	<p id="xdx_84A_eus-gaap--RevenueRecognitionIncentives_zXLfXylE6t0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zOf8tSfJTM19">Research and Development Incentive Income</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is eligible to obtain certain research and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”) and AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science (“AusIndustry”). The Australia R&D credit program provides for a cash refund based on a percentage of eligible research and development activities undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&D credit program to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Australia R&D credit program is available to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate of 18.5% above the claimant’s company tax rate in Australia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (“ASC 740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to the Australia R&D credit, as there is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant by analogy to IAS20 Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). The Company recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&D credit program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry, pursuant to an approved advanced overseas finding application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28851000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6300000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7618000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14271780	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13329616	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11540903	shares
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8790000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47498000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47620000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37641000	usd
CY2023Q3	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2006000	usd
CY2022Q3	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2031000	usd
CY2023Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1360000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1298000	usd
CY2023Q3	avxl	Fixed Contract Accruals FixedContractAccruals	38000	usd
CY2022Q3	avxl	Fixed Contract Accruals FixedContractAccruals	417000	usd
CY2023Q3	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	1267000	usd
CY2022Q3	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	137000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2624000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2062000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7295000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5945000	usd
CY2023	avxl	Grant Income GrantIncome	500000	usd
CY2022	avxl	Grant Income GrantIncome	0	usd
CY2021	avxl	Grant Income GrantIncome	500000	usd
CY2023	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	25000	usd
CY2022	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
CY2021	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	54100	usd
CY2023	avxl	Deferred Grant Income1 DeferredGrantIncome1	900000	usd
CY2022	avxl	Deferred Grant Income1 DeferredGrantIncome1	400000	usd
CY2023	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2700000	usd
CY2022	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	3300000	usd
CY2021	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4500000	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	2500000	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	2900000	usd
CY2023Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142400000	usd
CY2022Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142400000	usd
CY2023Q3	avxl	Fair Value Of Initial Commitment FairValueOfInitialCommitment	800000	usd
CY2023Q3	avxl	Incurred Expenses IncurredExpenses	100000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46462000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46208000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	118000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	73000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	131000	usd
CY2023	us-gaap	Pension Contributions PensionContributions	232000	usd
CY2022	us-gaap	Pension Contributions PensionContributions	158000	usd
CY2021	us-gaap	Pension Contributions PensionContributions	129000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2023Q3	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2022Q3	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	160000	shares
CY2023	avxl	Option Issued OptionIssued	3849917	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.94
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.69
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.54
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y9M
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16400000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18400000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8200000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34982000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	16370000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18379000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8231000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14100000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0370	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0311	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0073	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M20D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M25D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M26D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8513	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8417	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9343	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41198000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-40002000	usd
CY2023Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2713000	usd
CY2022Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2182000	usd
CY2021Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1577000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18593000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	13373000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10453000	usd
CY2023Q3	avxl	Deferred Tax Assets Research And Development Capitalization DeferredTaxAssetsResearchAndDevelopmentCapitalization	7219000	usd
CY2023Q3	avxl	Deferred Tax Assets Unpaid Charges DeferredTaxAssetsUnpaidCharges	1559000	usd
CY2022Q3	avxl	Deferred Tax Assets Unpaid Charges DeferredTaxAssetsUnpaidCharges	894000	usd
CY2021Q3	avxl	Deferred Tax Assets Unpaid Charges DeferredTaxAssetsUnpaidCharges	89000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	593000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	388000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	323000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	49000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	44000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	62000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	77188000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63089000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47486000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9975000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10000000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7934000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-170000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-353000	usd
CY2023	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation	-601000	usd
CY2022	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation	-714000	usd
CY2021	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation	-4379000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	165000	usd
CY2021	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m	816000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	273000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	741000	usd
CY2021	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382	3330000	usd
CY2023	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	-37000	usd
CY2022	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	232000	usd
CY2021	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	1042000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4122000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4975000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7022000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	206000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	24000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	48000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	216000	usd
CY2022	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes	358000	usd
CY2021	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes	268000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14098000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15603000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13495000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	358000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	268000	usd
CY2023	avxl	Operating Loss Carry Forwards Expiration Year OperatingLossCarryForwardsExpirationYear	2036
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	2700000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	2200000	usd
CY2023	avxl	Research And Development Tax Credits Year ResearchAndDevelopmentTaxCreditsYear	2029
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7200000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	800000	usd
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2500000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	800000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3300000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
avxl-20230930_pre.xml	Edgar Link	unprocessable
0001731122-23-002197-index-headers.html	Edgar Link	pending
0001731122-23-002197-index.html	Edgar Link	pending
0001731122-23-002197.txt	Edgar Link	pending
0001731122-23-002197-xbrl.zip	Edgar Link	pending
avxl-20230930.xsd	Edgar Link	pending
e5240_10k.htm	Edgar Link	pending
e5240_ex14-1.htm	Edgar Link	pending
e5240_ex21-1.htm	Edgar Link	pending
e5240_ex23-1.htm	Edgar Link	pending
e5240_ex23-2.htm	Edgar Link	pending
e5240_ex31-1.htm	Edgar Link	pending
e5240_ex31-2.htm	Edgar Link	pending
e5240_ex32-1.htm	Edgar Link	pending
e5240_ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.gif	Edgar Link	pending
image_002.gif	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
avxl-20230930_cal.xml	Edgar Link	unprocessable
avxl-20230930_def.xml	Edgar Link	unprocessable
avxl-20230930_lab.xml	Edgar Link	unprocessable
e5240_10k_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q4 Form 10-K Financial Statement

#000173112223002197 Filed on November 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q4 Form 10-K Financial Statement

#000173112223002197 Filed on November 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl